INTAS PHARMS USA
GenericsINTAS PHARMS USA is a generic drug manufacturer focused on Oncology.
INTAS PHARMS USA's Key Drugs
INTAS PHARMS USA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
INTAS PHARMS USA's Recent FDA Approvals
New NDA/BLA approvals for INTAS PHARMS USA over the last two years — novel drugs only, excluding generics and label supplements.
INTAS PHARMS USA's Therapeutic Areas
INTAS PHARMS USA's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INTAS PHARMS USA's Top Competitors
INTAS PHARMS USA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
INTAS PHARMS USA Pipeline Snapshot
Active clinical trials for INTAS PHARMS USA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2017-08-31
- Latest
- 2025-05-02
- Applications
- 2